171 related articles for article (PubMed ID: 37883794)
1. PF4 activates the c-Mpl-Jak2 pathway in platelets.
Buka RJ; Montague SJ; Moran LA; Martin EM; Slater A; Watson SP; Nicolson PLR
Blood; 2024 Jan; 143(1):64-69. PubMed ID: 37883794
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.
Greinacher A; Warkentin TE
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):1-10. PubMed ID: 38066843
[TBL] [Abstract][Full Text] [Related]
3. 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.
Kizlik-Masson C; Vayne C; McKenzie SE; Poupon A; Zhou Y; Champier G; Pouplard C; Gruel Y; Rollin J
J Thromb Haemost; 2017 Oct; 15(10):2065-2075. PubMed ID: 28771917
[TBL] [Abstract][Full Text] [Related]
4. Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review.
Warkentin TE; Greinacher A
Semin Thromb Hemost; 2023 Sep; 49(6):621-633. PubMed ID: 36455619
[TBL] [Abstract][Full Text] [Related]
5. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.
Visentin GP; Ford SE; Scott JP; Aster RH
J Clin Invest; 1994 Jan; 93(1):81-8. PubMed ID: 8282825
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia.
Huynh A; Arnold DM; Ivetic N; Clare R; Hadzi-Tosev M; Liu Y; Smith JW; Bissola AL; Daka M; Kelton JG; Nazy I
J Thromb Haemost; 2023 Oct; 21(10):2833-2843. PubMed ID: 37394121
[TBL] [Abstract][Full Text] [Related]
7. Platelet-activating anti-PF4 disorders: An overview.
Warkentin TE
Semin Hematol; 2022 Apr; 59(2):59-71. PubMed ID: 35512902
[TBL] [Abstract][Full Text] [Related]
8. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.
Newman PM; Chong BH
Blood; 2000 Jul; 96(1):182-7. PubMed ID: 10891449
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.
Kizlik-Masson C; Deveuve Q; Zhou Y; Vayne C; Thibault G; McKenzie SE; Pouplard C; Loyau S; Gruel Y; Rollin J
Blood; 2019 May; 133(22):2427-2435. PubMed ID: 30917957
[TBL] [Abstract][Full Text] [Related]
10. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia.
Huynh A; Kelton JG; Arnold DM; Daka M; Nazy I
Nature; 2021 Aug; 596(7873):565-569. PubMed ID: 34233346
[TBL] [Abstract][Full Text] [Related]
11. The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies.
Vayne C; Palankar R; Billy S; Handtke S; Thiele T; Cordonnier C; Pouplard C; Greinacher A; Gruel Y; Rollin J
Haematologica; 2022 Oct; 107(10):2445-2453. PubMed ID: 35385923
[TBL] [Abstract][Full Text] [Related]
12. Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia.
Favaloro EJ; Pasalic L; Henry B; Lippi G
Pathology; 2022 Apr; 54(3):254-261. PubMed ID: 35125202
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets.
Pitkänen HH; Jouppila A; Helin T; Dulipati V; Kotimaa J; Meri S; Kantele A; Jalkanen P; Julkunen I; Lassila R
Thromb Res; 2021 Dec; 208():129-137. PubMed ID: 34768097
[TBL] [Abstract][Full Text] [Related]
14. Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies.
Kanack AJ; Jones CG; Singh B; Leger RR; Splinter NP; Heikal NM; Pruthi RK; Chen D; George G; Abou-Ismail MY; Wool GD; Gundabolu K; Padmanabhan A
Blood; 2022 Dec; 140(25):2722-2729. PubMed ID: 35998675
[TBL] [Abstract][Full Text] [Related]
15. Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT.
Warkentin TE; Arnold DM; Sheppard JI; Moore JC; Kelton JG; Nazy I
J Thromb Haemost; 2023 Aug; 21(8):2268-2276. PubMed ID: 37182698
[TBL] [Abstract][Full Text] [Related]
16. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.
Greinacher A; Selleng K; Mayerle J; Palankar R; Wesche J; Reiche S; Aebischer A; Warkentin TE; Muenchhoff M; Hellmuth JC; Keppler OT; Duerschmied D; Lother A; Rieg S; Gawaz MP; Mueller KAL; Scheer CS; Napp M; Hahnenkamp K; Lucchese G; Vogelgesang A; Flöel A; Lovreglio P; Stufano A; Marschalek R; Thiele T;
Blood; 2021 Oct; 138(14):1269-1277. PubMed ID: 34280256
[TBL] [Abstract][Full Text] [Related]
17. Potential mechanisms of vaccine-induced thrombosis.
Marietta M; Coluccio V; Luppi M
Eur J Intern Med; 2022 Nov; 105():1-7. PubMed ID: 35953336
[TBL] [Abstract][Full Text] [Related]
18. Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder.
Venier LM; Clerici B; Bissola AL; Modi D; Jevtic SD; Radford M; Mahamad S; Nazy I; Arnold DM
Int J Hematol; 2023 Mar; 117(3):341-348. PubMed ID: 36574172
[TBL] [Abstract][Full Text] [Related]
19. The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia.
Singh A; Toma F; Uzun G; Wagner TR; Pelzl L; Zlamal J; Freytag V; Weich K; Nowak-Harnau S; Rothbauer U; Althaus K; Bakchoul T
Blood; 2022 Jun; 139(23):3430-3438. PubMed ID: 35679071
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia.
Horne MK; Hutchison KJ
Am J Hematol; 1998 May; 58(1):24-30. PubMed ID: 9590145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
